Drugs / GSK2789869A
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01934127 | Aug → Nov 2013 | influenza | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01949090 | Sep → Dec 2013 | influenza | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK2789869A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01949090 ↗ |
| Modality | Vaccine | “a novel AS03-adjuvanted H7N1 vaccine” PMID 28302407 ↗ Mar 2017 |
| Route | Intramuscular | “administered intramuscularly to the deltoid region” NCT01949090 ↗ |